Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Nicolo L. Cabrera; Ige A. George; Adriana M. Rauseo; Patrick Mazi; Andrej Spec

doi:10.1097/MOT.0000000000000995

Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Nicolo L. Cabrera, Ige A. George, Adriana M. Rauseo, Patrick Mazi, Andrej Spec

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Purpose of reviewRecipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.Recent findingsThese agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.SummaryThe properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.

Original language	English
Pages (from-to)	235-242
Number of pages	8
Journal	Current opinion in organ transplantation
Volume	27
Issue number	4
DOIs	https://doi.org/10.1097/MOT.0000000000000995
State	Published - Aug 1 2022

Keywords

antifungal drugs
invasive fungal infection
solid organ transplant

Access to Document

10.1097/MOT.0000000000000995

Cite this

@article{b5b261394cf1452cab8cfd2a996dc112,

title = "Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients",

abstract = "Purpose of reviewRecipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.Recent findingsThese agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.SummaryThe properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.",

keywords = "antifungal drugs, invasive fungal infection, solid organ transplant",

author = "Cabrera, {Nicolo L.} and George, {Ige A.} and Rauseo, {Adriana M.} and Patrick Mazi and Andrej Spec",

note = "Funding Information: N.L.C., I.A.G., A.M.R. and P.M. have nothing to disclose. A.S. received grants from Astellas and Mayne and consulting fees from Scynexis, Mayne, F2G and Theravance. Publisher Copyright: {\textcopyright} 2022 Lippincott Williams and Wilkins. All rights reserved.",

year = "2022",

month = aug,

day = "1",

doi = "10.1097/MOT.0000000000000995",

language = "English",

volume = "27",

pages = "235--242",

journal = "Current opinion in organ transplantation",

issn = "1087-2418",

number = "4",

}

TY - JOUR

T1 - Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

AU - Cabrera, Nicolo L.

AU - George, Ige A.

AU - Rauseo, Adriana M.

AU - Mazi, Patrick

AU - Spec, Andrej

N1 - Funding Information: N.L.C., I.A.G., A.M.R. and P.M. have nothing to disclose. A.S. received grants from Astellas and Mayne and consulting fees from Scynexis, Mayne, F2G and Theravance. Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - Purpose of reviewRecipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.Recent findingsThese agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.SummaryThe properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.

AB - Purpose of reviewRecipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.Recent findingsThese agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.SummaryThe properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.

KW - antifungal drugs

KW - invasive fungal infection

KW - solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=85141495021&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000995

DO - 10.1097/MOT.0000000000000995

M3 - Review article

C2 - 36354248

AN - SCOPUS:85141495021

SN - 1087-2418

VL - 27

SP - 235

EP - 242

JO - Current opinion in organ transplantation

JF - Current opinion in organ transplantation

IS - 4

ER -

Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this